PLASBUMIN-25 INJECTION 25% Singapore - inglese - HSA (Health Sciences Authority)

plasbumin-25 injection 25%

grifols asia pacific pte. ltd. - albumin (human) - injection - 5 g/20 ml - albumin (human) 5 g/20 ml

PLASMANATE INJECTION 5% Singapore - inglese - HSA (Health Sciences Authority)

plasmanate injection 5%

grifols asia pacific pte. ltd. - plasma proteins (human) - injection - 5 g/100 ml - plasma proteins (human) 5 g/100 ml

Polychloroprene surgical glove, non-powdered Australia - inglese - Department of Health (Therapeutic Goods Administration)

polychloroprene surgical glove, non-powdered

mediflex industries pty ltd - 57970 - polychloroprene surgical glove, non-powdered - a sterile device made of polychloroprene (neoprene) intended as a protective barrier when worn on the hands of healthcare providers at the surgical site. it is used mainly as a two-way barrier to protect patient and staff from microorganisms and risk of allergy to latex. it will have appropriate characteristics regarding tactility and comfort of use, and should provide adequate conditions of sterility, appropriate physical properties (e.g., tensile strength, resistance to puncture, elasticity), and uniformity of dimensions (i.e., sizing consistency). this is a single-use device.

Polychloroprene examination/treatment glove, non-powdered Australia - inglese - Department of Health (Therapeutic Goods Administration)

polychloroprene examination/treatment glove, non-powdered

mediflex industries pty ltd - 56288 - polychloroprene examination/treatment glove, non-powdered - non-sterile device made of polychloroprene (neoprene) intended as a protective barrier when worn on the hands of healthcare providers during patient examination/treatment or for other sanitary purposes. the device is used mainly as a two-way barrier to protect patient/staff against contaminants and risk of allergy to latex. it will have appropriate characteristics regarding tactility and comfort of use, and should provide appropriate physical properties (e.g., tensile strength, resistance to puncture, elasticity), and uniformity of dimensions (i.e., sizing consistency). this is a single-use device.

ONDANSETRON- ondansetron tablet, orally disintegrating Stati Uniti - inglese - NLM (National Library of Medicine)

ondansetron- ondansetron tablet, orally disintegrating

lake erie medical dba quality care products llc - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 4 mg - 1. prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m2 . 2. prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets, ondansetron orally disintegrating tablets, and ondansetron hydrochloride oral solution are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindic